Teladoc Health (TDOC) faces elevated risk of missing consensus estimates for its Q3 2026 results, scheduled for release after market close on October 28, amid ongoing revenue contraction and prior-quarter shortfalls. Analysts project revenue near $588–622 million, below year-ago levels, following Q2’s $606.93 million print that missed estimates by 3–6%. The company’s September guidance of $569–609 million in revenue underscored downside pressure, while EPS consensus around –$0.21 reflects modest improvement from adjusted losses. Recent share-price weakness, mixed analyst ratings centered on Hold, and persistent telehealth utilization challenges have reinforced trader skepticism, outweighing incremental AI platform updates and leaving limited room for an upside surprise relative to market-implied odds.